Privia Health Q1 Revenue Beats Estimates, But EPS Miss Sends Stock Down 11%

Privia Health (NASDAQ:PRVA) shares fell 11.1% since reporting Q1 2026 results, as of June 5, 2026, despite revenue surging 25.8% year-on-year to $603.8 million, exceeding analysts’ forecasts by 7.4%. A significant earnings-per-share miss weighed on the stock, which traded at $21.34. The broader healthcare technology for providers group, including Omnicell (OMCL), Evolent Health (EVH), and Astrana Health (ASTH), topped aggregate revenue estimates by 1.1%. Omnicell jumped 15.9% after beating EPS and raising guidance. Evolent advanced 14.4% despite a revenue miss, while Astrana Health delivered 55.6% revenue growth but issued full-year guidance below expectations. The sector benefits from AI-driven tools and value-based care models, though tight hospital budgets and slow provider adoption pose headwinds.